Clinical trials: Autoinflammatory Disease
Muckle Wells Syndrome
Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome
This study is designed to provide efficacy and safety data for ACZ885 (a fully human anti-interleukin-1beta (anti-IL-1beta) monoclonal antibody) administered as an injection subcutaneously (s.c.) in patients with Muckle-Wells…
- Trial name
- REMITTER (NCT00465985)
- Testing
- ACZ885
- Where
- 12 sites in United States, France and 4 more
- Volunteers
- 35 people
- Sponsor
- Novartis
Behcet's Disease, Behcet Syndrome
Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of TA-650 in patients with Behcet's disease ( BD ) with special lesions after the administration of TA-650 at a dosage of 5 mg/kg in weeks 0, 2…
- Conditions
- Behcet's Disease, Behcet Syndrome, Neuro-Behcet's Disease
- Trial name
- NCT01532570
- Testing
- TA-650
- Where
- 6 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Tanabe Pharma Corporation
Fluid Loss, Symptom Complex, Triple
Saline vs. Lactated Ringers for Emergency Department IV Fluid Resuscitation
Administration of intravascular (IV) fluid is the most common emergency department (ED) procedure. IV fluids are integral to increasing effective blood volume and ensuring organ perfusion in patients with volume depletion and…
- Conditions
- Fluid Loss, Symptom Complex, Triple, Emergencies
- Trial name
- NCT03133767
- Testing
- Lactated Ringer Solution, Normal Saline 0.9% Infusion Solution Bag
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- Nicholas M Mohr
Systemic Juvenile Idiopathic Arthritis, Hereditary Periodic Fevers
A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies
The objective of this extension protocol is to collect safety data (serious and non-serious adverse events) and to provide continuous canakinumab to patients in France who completed study CACZ885G2301E1(NCT00891046), CACZ885G2306…
- Trial name
- NCT02334748
- Testing
- canakinumab
- Where
- 3 sites in France
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Familial Mediterranean Fever
Rilonacept for Treatment of Familial Mediterranean Fever (FMF)
Familial Mediterranean fever (FMF) is a genetic disease resulting in recurrent attacks of fever, abdominal pain, chest pain, arthritis and rash.
- Trial name
- NCT00582907
- Testing
- Rilonacept
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- The Cleveland Clinic